85 related articles for article (PubMed ID: 1327941)
21. Mucinous adenofibroma of the ovary: case report of the endocrinologic findings.
Tohya T; Mizutani H; Katabuchi H; Miyazaki K; Okamura H
Gynecol Oncol; 1994 Aug; 54(2):218-21. PubMed ID: 8063250
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
23. Actions of gonadotropin-releasing hormone analogues in pituitary gonadotrophs and their modulation by ovarian steroids.
Weiss JM; König SJ; Polack S; Emons G; Schulz KD; Diedrich K; Ortmann O
J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):118-26. PubMed ID: 16891115
[TBL] [Abstract][Full Text] [Related]
24. Steroid biosynthesis in the Sertoli-Leydig cell tumor: effects of insulin and luteinizing hormone.
Nagamani M; Stuart CA; Van Dinh T
Am J Obstet Gynecol; 1989 Dec; 161(6 Pt 1):1738-43. PubMed ID: 2532472
[TBL] [Abstract][Full Text] [Related]
25. Bilateral microscopic Leydig cell ovarian tumors in the postmenopausal woman.
Langevin TL; Maynard K; Dewan A
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370966
[TBL] [Abstract][Full Text] [Related]
26. Direct in-vivo detection of atypical hormonal expression of a Sertoli-Leydig cell tumour following stimulation with human chorionic gonadotrophin.
Cohen I; Shapira M; Cuperman S; Goldberger S; Siegal A; Altaras M; Beyth Y
Clin Endocrinol (Oxf); 1993 Oct; 39(4):491-5. PubMed ID: 8287578
[TBL] [Abstract][Full Text] [Related]
27. An unusual steroid-producing ovarian tumour: case report.
Stephens JW; Katz JR; McDermott N; MacLean AB; Bouloux PM
Hum Reprod; 2002 Jun; 17(6):1468-71. PubMed ID: 12042263
[TBL] [Abstract][Full Text] [Related]
28. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and resection of an oral contraceptive-suppressible Sertoli-Leydig cell tumor with preservation of fertility and a 7-year follow-up.
Haning RV; Loughlin J; Shapiro SS
Obstet Gynecol; 1989 May; 73(5 Pt 2):901-5. PubMed ID: 2523030
[TBL] [Abstract][Full Text] [Related]
30. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
[TBL] [Abstract][Full Text] [Related]
31. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
[TBL] [Abstract][Full Text] [Related]
32. Gonadotropin release in periovulatory heifers after GnRH analogs measured by two types of immunoassays.
Schneider F; Bellmann A; Becker F; Bambang Poernomo S; Rehfeldt C; Nürnberg G; Kanitz W
Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):235-44. PubMed ID: 12148088
[TBL] [Abstract][Full Text] [Related]
33. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
[TBL] [Abstract][Full Text] [Related]
34. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
[TBL] [Abstract][Full Text] [Related]
35. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
[TBL] [Abstract][Full Text] [Related]
36. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
[TBL] [Abstract][Full Text] [Related]
37. [Hyperthecosis ovarii--a tumor-like change in androgenized females].
Schwartz U; Moltz L; Pickartz H; Sörensen R; Römmler A
Geburtshilfe Frauenheilkd; 1986 Jun; 46(6):391-7. PubMed ID: 3091442
[TBL] [Abstract][Full Text] [Related]
38. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
Wide L; Albertsson-Wikland K; Phillips DJ
J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754
[TBL] [Abstract][Full Text] [Related]
39. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
40. Leuprolide suppression of androgen secretion by hilus cell hyperplasia within the wall of an ovarian cyst.
de Santiago M; Herranz L; Ordas J; Atienza M; Suarez-Mier M; Gancedo PG
Clin Endocrinol (Oxf); 1996 Aug; 45(2):239-42. PubMed ID: 8881459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
